Skip Navigation
Skip Website Tools
Zonghui Hu photo

Contact Info

Zonghui Hu, Ph.D.
6700B Rockledge Drive
Bethesda, MD 20892-7609
Phone: 301-451-2434
Fax: 301-480-0912
huzo@niaid.nih.gov

Overnight mail address:
6700-A Rockledge Drive, Room 5231
Bethesda, MD 20817

Biostatistics Research Branch (BRB)

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Zonghui Hu, Ph.D.

Mathematical Statistician

Interests

Functional data analysis, semiparametric models, measurement error models, longitudinal data analysis, generalized models, biostatistics.

Additional Information

Curriculum Vitae (PDF)

Selected StatisticalPublications

  • Hu Z, Follmann DA, Wang N. “Effective balancing score for mean response estimation.” Biometrika, 2014.
  • Hu Z, Qin J, Follmann DA. “Semiparametric mixture survival model with application to MRFIT study.” Statistics and Its Interface, 7: 19–26, 2014.
  • Hu Z, Follmann DA. “ Acute-to-chronic ratio as a metric for HIV surveillance.” Open Journal of Statistics, 4: 111–117, 2014.
  • Hu Z, Follmann DA, Qin J. “Semiparametric double balancing score estimation for incomplete data with ignorable missingness.” Journal of American Statistical Association, 107: 247–257, 2012.
  • Hu Z, Follmann DA, Qin J. “Dimension reduced kernel estimation for distribution function with incomplete data.” Journal of Statistical Planning and Inference, 141: 3084–3093, 2011.
  • Hu Z, Follmann DA, Qin J. “Semiparametric dimension reduction estimation for mean response with missingness.” Biometrika, 97: 301–319, 2010.
  • Brittain E and Hu Z “Non-inferiority trial design and analysis with an ordered three-level categorical endpoint.” Journal of Biopharmaceutical Statistics, 19: 685–699, 2009.
  • Hu Z, Qin J, Follmann DA. “Semiparametric two-sample change-point model.” Journal of Royal Statistical Society Series C, 57: 589–607, 2008.
  • Hu Z, Wang N. “Semiparametric mixed-effects model with latent covariate in Colon carcinogenesis study.” Statistics and Its Interface, 1: 75–86, 2008.
  • Hu Z, Qin J, Follmann DA, Dewar R. “Nonparametric likelihood approach for assessing the accordance between two measurements and its application to viral load determination with limit of detection.” Statistics in Medicine, 27: 4489–4501, 2008.
  • Hu Z, Follmann DA. “Statistical methods for active extension trials.” Statistics in Medicine, 26:2433–2448, 2007.
  • Hu Z, Wang N, Carroll RJ. “Profile-Kernel versus backfitting in the partially linear models for longitudinal/clustered data.” Biometrika, 91:251–262, 2004.

Selected Medical Publications

  • Ledgerwood J, Zephir K, Hu Z, Wei CJ, Chang LJ, Enama M, Hendel S, Sitar S, Bailer R, Koup R, Mascola J, Nabel G, Graham B and the VRC 310 Study Team. “Boost interval matters: a randomized phase I study to identify the minimum interval to observe the H5 DNA influenza vaccine priming effect.“ Journal of Infectious Disease, 208(3):418–422, 2013.
  • Miura K, Herrera R, Diouf A, Zhou H, Mu J, Hu Z, MacDonald N, Reiter K, Nguyen V, Shimp R, Singh K, Narum D, Long C, Miller L. “Overcoming allelicspecificity by immunization with 5-allelic forms of Plasmodium falciparum Apical Membrane Antigen 1.” Infection and Immunity, 81(5):1491–1501, 2013.
  • Ledgerwood JE, Hu Z, Gordon IJ, Yamshchikov G, Enama ME, Plummer S, Bailer R, Tumpey TM, Koup RA, Mascola JR, Nabel GJ, Graham BS and the VRC 304 and VRC 305 Study Teams. “H5 DNA Influenza Vaccination is Immunogenic by Intradermaland Intramuscular Routes in Humans.” Clinical and Vaccine Immunology.
  • Enama ME, Hu Z, Gordon I, Costner P, Ledgerwood JE, Grady C. “Comparison of standard and simplified consent forms in investigational influenza vaccine clinical trials.” Contemporary Clinical Trials, 33: 895–902, 2012.
  • Osinusi A, Naggie S, Poonia S, Trippler M, Hu Z, Schlaak JF, Fishbein D, Masur H, Polis MA, Kottilil S. “ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in HIV/HCV co-infected patients.” Journal of Medical Virology, 84: 1106-1114, 2012.
  • Sneller MC, Hu Z, Langford CA. “A Randomized Controlled Trial of Rituximab Following Failure of Antiviral Therapy for Hepatitis C-Associated Cryoglobulinemic.” Arthritis & Rheumatism, 64: 835–842, 2012.
  • Ledgerwood JE,Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, McTamney PM, Yassine H, Bailer R, Tumpey TM. Koup RA, Mascola JR, Nabel GJ, Graham BS1 and the VRC 306 Study Team (2011). “DNA priming improves influenza vaccine immunogenicity in humans.” Lancet, 11:912–924, 2011.
  • Hodge JN, Srinivasula S, Hu Z, Read SW, Porter BO, Mican J, Paik C, Di Mascio M, Sereti I. “Decreases in IL-7 levels during ART suggest a primary mechanism of receptor-mediated clearance with IL-7 levels normalizing despite persistent CD4 lymphopenia.” Blood, 118:3244–3253, 2011.
  • Matthews GV, Manzini P, Hu Z, Khabo P, Maja P, Mutchaba G, Sangweni P, Metcalf J, Pool N, Orsega S, Emery S on behalf of the PHIDISA II study team. “Impact of 3TC on HIV and HBV related outcomes in HIV/HBV individuals in a randomized clinical trial of antiretroviral therapy in South Africa.” AID, 14:1727– 1735, 2011.
  • Dlamini J, Hu Z, Morris L, Somaroo H, Ledwaba J, Maldarelli F, Highbarger H, Sangweni P, Follman D, Dewar R, Pau A, and the Phidisa Study Group. “Genotypic Resistance at Viral Rebound among Patients Who Received Lopinavir/ritonavir-or Efavirenz-Based First Antiretroviral Therapy in South Africa.” Journal of Acquired immune Deficiency Syndrome, 58:304–308, 2011.
  • Dlamini J, Hu Z, Somaroo H, Highbarger H, Sangweni P, Follman D, Dewar R, Pau A. “Lack of effect from a previous single dose of Nevirapine on virologic and immunologic responses after 6 months of antivetroviral regimens containing efavirenz or lopinavir-ritonavir.” Pharmacotherapy, 31: 158–163, 2011.
  • Komarow H, Hu Z, Brittain E, Uzzaman A, Gaskins D, Metcalfe DD. “Serum tryptase levels in atopic and non-atopic children.” Journal of Allergy and Clinical Immunology, 124: 845–848, 2009.
  • Catalfamo M, Di Mascio M, Hu Z, Srinivasula S, Thaker V, Adelsberger J, Rupert A, Baseler M, Tagaya Y, Roby G, Rehm C, Follmann D, Lane C. “HIV infection associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells.” Proceedings of the National Academy of Sciences of the United States of America, 105: 19851–19856, 2008.
  • Suzman DL, McLaughlin M, Hu Z, Kleiner DE, Wood B, Vailati M, Lempicki RA, Mican JM, Suffredini A, Masur F, Polis MA, Kottilil S. “Identification of novel markers for liver fibrosis in HIV/HCV co-infected individuals using genomics-based approach.” AIDS, 22: 1433–1439, 2008.
  • Highbarger HC, Hu Z, Kottilil S, Metcalf JA, Polis MA, Vasudevachari MB, Lane CH, Dewar R. “Comparison of the Abbott 7000 and Bayer 340 systems for measurement of Hepatitis C viral load.” Journal of Clinical Microbiology, 45: 2808–2812, 2007.
  • Pau AK, McLaughlin M, Hu Z, Polis MA, Kottilil S. “Predictors for Hematopoietic Growth Factors Use in HIV/HCV Co-Infected Patients Treated with Peginterferon alfa 2b and Ribavirin.” AIDS Patient Care and STDs, 9: 612–619, 2006.

back to top

Last Updated June 06, 2014